Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) and Moderna (NASDAQ:MRNA – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Institutional & Insider Ownership
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Arcturus Therapeutics has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
Profitability
This table compares Arcturus Therapeutics and Moderna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcturus Therapeutics | -285.92% | -46.79% | -36.50% |
| Moderna | -110.46% | -25.79% | -15.85% |
Valuation & Earnings
This table compares Arcturus Therapeutics and Moderna”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arcturus Therapeutics | $82.03 million | 2.94 | -$65.78 million | ($3.08) | -2.71 |
| Moderna | $2.52 billion | 35.87 | -$2.82 billion | ($7.10) | -31.46 |
Arcturus Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for Arcturus Therapeutics and Moderna, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcturus Therapeutics | 1 | 0 | 6 | 2 | 3.00 |
| Moderna | 4 | 15 | 6 | 0 | 2.08 |
Arcturus Therapeutics presently has a consensus target price of $24.50, suggesting a potential upside of 193.06%. Moderna has a consensus target price of $113.75, suggesting a potential downside of 49.08%. Given Arcturus Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Arcturus Therapeutics is more favorable than Moderna.
Summary
Arcturus Therapeutics beats Moderna on 9 of the 14 factors compared between the two stocks.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company’s pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products.
About Moderna
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
